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Blood and marrow transplantation (BMT) is a potentially curative therapy for a number of malignant and
nonmalignant diseases. Multiple variables, including age, comorbid conditions, disease, disease stage, prior
therapies, degree of donor-recipient matching, type of transplantation, and dose intensity of the preparative
regimen, affect both morbidity and mortality. Despite tremendous gains in supportive care, BMT remains a
high-risk medical therapy. A critically ill BMT recipient may require transfer to an intensive care unit (ICU)
and the specialized medical and nursing care that can be provided, such as mechanical ventilation and
vasopressor support. Mortality for BMT recipients requiring care in an ICU is high. This paper will describe the
experience of the Stanford Blood and Marrow Transplant Program in developing and implementing guide-
lines to maximize the beneﬁt of intensive care for critically ill BMT recipients.
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTION Key variables evaluated included number of patients trans-
Mortality for blood and marrow transplantation (BMT)
recipients requiring intensive care unit (ICU) interventions has
ranged fromgreater than70%tonearly100%over thepast2 to3
decades [1-4]. Advances in the ﬁelds of both BMT and critical
care in recent years have included many factors that may
potentially decrease mortality, including reduced-intensity
conditioning, improved antimicrobial agents, and improve-
ments in themanagement of sepsis and respiratory failure [5].
More recent reports showmodest improvement in the survival
of BMTpatients requiring ICU care; however, themortality rate
remains high at approximately 70% to 85%, with variable
determinants, such as needs for vasopressor support, renal
replacement therapy, or mechanical ventilation [6-8]. Models
that reliably predict outcomes and guide clinical decision-
making for the critically ill BMT patient are needed [5,9].
In 1994, the Stanford Adult BMT Program began to sys-
tematically review utilization of the ICU for BMT recipients.dgments on page 2027.
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ty for Blood and Marrow Transplantation.ferred to the ICU, reasons for transfer, length of stay (LOS) in
the ICU, and survival outcomes. Between 1994 and 1998, 92
BMT recipients were transferred to the ICU with an overall
hospital mortality of 92.4%, and at this time we developed
our ﬁrst guidelines for ICU care. In subsequent years, there
was a rise in the number of patients transferred to the ICU as
well as an increase in ICU LOS, despite continued high mor-
tality. The increase in ICU utilization without clear
improvement in survival spurred us to critically re-evaluate
our ICU utilization. Our objective was to develop criteria for
ICU transfer and continued ICU care to maximize the beneﬁt
of intensive care for critically ill BMT recipients, without
submitting patients to burdensome care without value. This
report describes the Stanford Adult BMT Program’s experi-
ence in creating guidelines for transfer and continuing care
in the ICU.METHODS
In 2005, an ICU utilization project teamwas created and included a BMT
attending physician, social worker, nurse manager, and the ICU medical
director. The team deﬁned the objectives of the ICU project as follows:
(1) develop criteria to help determinewhom to transfer to the ICU andwhen
to re-evaluate, (2) decrease average ICU LOS without negatively affecting
hospital mortality, and (3) decrease the number of patients admitted to the
P. Jenkins et al. / Biol Blood Marrow Transplant 21 (2015) 2023e20272024ICU who would not beneﬁt from it based on established criteria. Beginning
in 2005, all adult BMT recipients admitted to the ICU were reviewed for
appropriateness of care and compliance with the ICU guidelines. In deter-
mining if the ICU transfer was appropriate, the initial indication for transfer
is utilized.
In developing the guidelines, we reviewed our past use of the ICU,
outcomes, and clinical experience as well as the published literature of
ICU use related to BMT. From 1994 to 1998, 92 of 1001 patients who un-
derwent transplantationwere transferred to the ICU and 85 (92.4%) of these
individuals died. Primary causes of death included infection, pulmonary
damage, multiorgan failure, graft-versus-host disease (GVHD), central ner-
vous system bleeding, and relapse. Of the 7 recipients who survived the ICU
stay, 6 were never intubated and 1 was intubated for less than 24 hours. In
addition to appraising our experience, reviewing the literature was critical
to developing the criteria to guide decision-making regarding ICU care. The
literature review also provided prognostic information that could be used in
counseling patients and families during the decision-making process. Sub-
sequently, we developed 3 categories to guide our decisions on who to
transfer to the ICU, shown in Table 1.
Individuals who fall into the category of “no ICU recommended” include
those with grade III and IV acute GVHD who do not respond to ﬁrst-line
therapy, deﬁned as therapy with corticosteroids dosed at 2 mg/kg/day for 7
days. Reported mortality for these individuals ranges from 70% to 95% [10].
Those individuals who have relapsed malignancy after transplantation are
also included in the no ICU recommended group, as outcomes are generally
quite poor [11,12]. The third group of individuals in this category includes
those with multiorgan failure and requiring mechanical ventilation. Multi-
organ failure is deﬁned as grade 4 toxicity of individual organs based on the
National Cancer Institute Common Terminology Criteria for Adverse Events
version 4. The Common Terminology Criteria for Adverse Events deﬁnes
grade 4 toxicities as those that are life threatening requiring urgent inter-
vention [13]. Mechanical ventilation is consistently reported to be associated
with high mortality [8,14].
Patients who are recommended for ICU care include those with sinu-
soidal obstructive syndrome with mild to moderate disease who can expect
resolution with supportive care [15]. Severe cases of sinusoidal obstructive
syndrome leading to multiorgan failure have a mortality rate approaching
85% and would fall into the “no ICU recommended category” [15]. In-
dividuals who are transferred to the ICU for hypoxemia not requiring intu-
bation generally do well. Our own data from 1994 to 1998 showed that the 7
patients transferred to the ICU who survived were either never intubated or
intubated for fewer than 24 hours. Sepsis without hypotension, hypoten-
sion, diffuse alveolar hemorrhage, cardiac events, and airway protection are
indications that transfer to the ICU is recommended. Based on our own data
and experience and the literature, these events can often be successfully
treated with the specialized interventions available in the ICU.
Respiratory failure requiring mechanical ventilation falls into the
“limited ICU recommended” category with re-evaluation after 3 days. Fluid
overload or congestive heart failure may precipitate respiratory failureTable 1
ICU Admission Categories
Category Indications
ICU care
recommended
Sinusoidal obstructive syndrome
Hypoxemia not requiring intubation especially
if volume overloaded or transfusion-related
acute lung injury
Sepsis without hypotension
Hypotension
Diffuse alveolar hemorrhage
Cardiac event: an event leading to
cardiovascular instability requiring either
treatment of an arrhythmia or ﬂuid support
Airway protection in the setting of severe
oropharyngeal mucosal injury or alteredmental
status
Limited ICU
recommended*
Severe sepsis requiring intubation or
vasopressors
Respiratory failure requiring intubation
No ICU
recommended
Grade III-IV acute (GVHD) unresponsive to
treatment with respiratory failure
Relapsed disease if further treatment is not an
option
Multiorgan failure and requiring intubation
(2 failed organs and mechanical ventilation)
* Re-evaluate within 3 days of ICU admission.requiringmechanical ventilation, but these events generally respond rapidly
to therapy. Severe sepsis requiring intubation or vasopressors also falls into
the category of limited ICU recommended. The key for individuals in this
category is the single-organ failure and reassessment after 3 days, at which
time recommendations for continued ICU care or comfort care are based on
the response to therapy.
A fourth goal of the ICU utilization project was to develop a protocol for
communication between the BMT and ICU medical teams and the patient
and family while the patient remains in the ICU. The communication pro-
tocol consists of daily mandatory meetings among the BMT team, including
the BMT social worker, BMT nurse manager, and the ICU team. An ICU team
member summarizes the events of the past 24 hours and together the 2
medical teams establish the goals of care for the day. The BMT social worker
arranges family meetings every 3 days to facilitate communication and
discuss goals of care. Both the ICU and BMT medical teams attend the family
meetings to ensure consistent information is presented to the patient and
family regarding the clinical situation and recommendations for care.Data Analysis
Chart reviews were conducted to collect demographic data, medical
histories, and transplantation details. Transfer to the ICU, ICU LOS, ICU in-
terventions, and patient outcomes were collected prospectively. Descriptive
statistics were calculated for all patients transferred to the ICU. Chi-square
tests were conducted to evaluate the incidence of hospital mortality in
relationship to ICU category and ICU interventions.
The primary outcome was hospital mortality, deﬁned as death during
hospitalization or within 7 days of discharge. To explore the variables
associated with hospital mortality, a univariate chi-square analysis for each
variable was completed followed by multivariate logistic regression
modeling. Demographic and clinical variables were entered into the model
in 4 blocks. The ﬁnal model with all clinical variables included is reported.
Finally, a ﬁnancial analysis was conducted to compare the cost of caring for
patients in the ICU compared with the cost in the BMT unit.RESULTS
Patient Characteristics
The Stanford Adult BMT Program performed 2008 trans-
plantations from ﬁscal year (FY) 2008 to FY 2014. During this
time period, 234 patients were transferred to the ICU. The
characteristics of the BMT patients transferred to the ICU are
summarized in Table 2. Sixty-nine of the 234 patients had
more than 1 admission to the ICU, for a total of 303 ICU
admissions. The median age of those transferred to the ICU
was 51 years, and the majority were male (59%) and Cauca-
sian (66%). The most frequent transplantation diagnosis was
acute leukemia (41%) and 72% received a myeloablative
allogeneic transplant.Mortality
The hospital mortality for the 234 patients was 55%. For
those individuals within the categories of ICU recommended,
limited ICU recommended, and no ICU recommended, mor-
tality was 26%, 55%, and 100%, respectively. There was a
signiﬁcant relationship between the 3 categories of ICU
recommendations and death (P ¼ .001). In the 303 ICU ad-
missions, 52.1% required vasopressor support, 54.5% needed
mechanical ventilation, and 35% required both mechanical
ventilation and vasopressor support. Table 3 summarizes
outcomes for the 303 ICU admissions based on ICU category
and interventions. Hospital mortality for those requiring
both mechanical ventilation and vasopressors was 71%
(n ¼ 76) versus a mortality of 24% (n ¼ 21) for those who did
not require either intervention (P < .0005; diff .49; 95%
conﬁdence interval, .35 to .061).
A hematopoietic cell transplantation comorbidity index
(HCT-CI) was available for 71.3% of the 234 patients trans-
ferred to the ICU. There was no signiﬁcant difference in
hospital mortality between those with a HCT score of 0 to 3
versus those with an HCT-CI score of 4 to 8. The hospital
Table 2
Characteristics of Patients Transferred to the ICU between FY 2008 and FY
2014 (n ¼ 234)
Characteristic Value
Age, median (range), yr 51 (19-74)
Male 139 (59.4)
Female 95 (40.6)
Race
Asian 31 (13.8)
Black 6 (2.7)
Unknown 35 (15.6)
White 148 (65.8)
Other 5 (2.2)
Diagnosis
Acute leukemia 89 (40.5)
Chronic leukemia 16 (7.3)
Non-Hodgkin lymphoma 54 (24.5)
Myelodysplastic syndrome 20 (9.1)
Multiple myeloma 17 (7.7)
Other 24 (11.1)
Type of transplantation*
Autologous 48 (21.3)
Allogeneic 177 (78.7)
Donor matching
HLA-identical sibling 80 (35.6)
HLA-mismatched relative 4 (1.8)
HLA-matched unrelated donor 65 (28.9)
HLA-mismatched unrelated donor 28 (12.4)
Allogeneic preparative regimen*
Myeloablative 162 (72)
Reduced-intensity conditioning 63 (28)
Acute GVHD 85 (36.3)
Died 104 (44.4)
Data presented are n (%), unless otherwise indicated.
* Missing data on 9 individuals who received a transplant at another
center.
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versus 68.4% for those with a score of 4 to 8 (P ¼ .283).
LOS
Patients were transferred to the ICU amedian of 73.5 days
(0 to 3219 days) after transplantation. The median ICU LOS
was 5 days (range, <1 day to 43 days). The ICU LOS was <5
days for 53.7% of patients, 5 to 15 days for 33.9% of patients,
and >15 days for 12.4% of patients. There was a signiﬁcant
relationship between ICU LOS and death. Individuals with
an ICU LOS <5 days had a hospital mortality of 33% versus
a hospital mortality of 60% for individuals with an ICU
LOS > 15 days (P ¼ .001; diff .25; 95% conﬁdence interval,
.07 to .4).
Regression Analysis
A univariate chi-square analysis for each variable was
completed followed by the developing of a multivariate lo-
gistic regression model to identify the variables that mightTable 3
Hospital Mortality for 303 ICU Admissions* Based on Category of Recommendation
Category No Vasopressors
or Mechanical
Ventilation
Vasopr
Only
n Died, n (%) n
ICU recommended (n ¼ 122) 85 19 (22) 17
Limited ICU recommended (n ¼ 167) 1 1 (100) 31
No ICU recommended (n ¼ 14) 1 1 (100) 3
Total 87 21 (24%) 51
* Of the 234 patients in this cohort, 69 had more than 1 ICU admission and 128predict mortality. The following 4 blocks of variables were
entered into the model: block 1 (age, gender, and race), block
2 (product, ablative preparative regimen, donor), block 3
(acute GVHD, mechanical ventilation, and/or vasopressor),
and block 4 (ICU days). A ﬁnal model, with all explanatory
variables entered, explained 35% of the total variance in
mortality. Table 4 shows the results of the univariate and
multivariate analysis. Of those variables entered, only 2
variables were signiﬁcantly associated with mortality when
adjusted for all other variables: age greater than 55 years and
the combination of mechanical ventilation with vasopressor
support.
Finance
Signiﬁcant ICU resources were allocated for the care of the
13 patients (1 patient had 2 ICU admissions) who did not
meet criteria for ICU admission. Financial data for 12 patients
were available for analysis between the years of 2010 to 2013.
ICU care accounted for 21% of total hospitalization charges. A
total of 53 ICU days were associated with the 12 patients,
with amean ICU LOS of 4.4 days (range,1 to 12 days). Average
charge per day in the ICUwas 2.1 times that the cost of care in
the BMT unit.
DISCUSSION
Our ICU utilization project resulted in the development of
criteria for transfer of BMT patients to the ICU and is one of
the largest cohorts of BMT patients receiving ICU care that
has been reported. We developed 3 categories that can reli-
ably predict hospital mortality for patients transferred to the
ICU at our institution. Based on the categories, we expected
the largest number of survivors to fall in the category of ICU
recommended. In the 303 ICU admissions, 122 fell into the
category of ICU recommended and the survival rate was 76%.
Thirteen patients (1 patient was transferred twice) were
transferred to the ICU despite falling into the group of no ICU
recommended and there were no survivors. The 100% mor-
tality for these 13 patients support our category of no ICU
recommended.
The category of limited ICU represents the most difﬁcult
patient population. The clinical course can wax and wane
over a signiﬁcant period of time. Slightly over one half (52%)
of the patients admitted to the ICU in this category died. The
category is titled “limited ICU” and the data support that
thosewith a short ICU stay (<5 days) have a mortality of 33%,
which is signiﬁcantly lower than the 60% mortality for those
with a longer ICU stay (>15 days). Our data are consistent
with other reports in the literature supporting the view that
patients who do not make rapid clinical improvement in the
ICU have poorer outcomes [14]. ICU LOS is 1 variable that can
assist health care providers, patients, and families in
deciding when to shift the goals of care to comfort. Otherand ICU Interventions
essors Mechanical
Ventilation Only
Both Vasopressors
and Mechanical
Ventilation
Died, n (%) n Died, n (%) n Died, n (%)
3 (18) 13 2 (15) 7 5 (71)
3 (10) 41 18 (44) 94 65 (69)
3 (100) 4 4 (100) 6 6 (100)
8 (14%) 58 23 (45%) 107 76 (71%)
died (55% of total patients).
Table 4
Univariate and Multivariate Regression Modeling Predicting Likelihood of
Hospital Death for Patients Who Required ICU Care
Factor Mortality
n (%)
Univariate Multivariate*
Chi-square,
df
P Value OR (95% CI) P Value
Age:
<55 yr 72 (41) 1.58, 1 .22 2.9 (1.2-7.1) .017
>55 yr 56 (48)
Sex:
Female 58 (48) 1.54, 1 .21 .78 (.42-1.4) .416
Male 73 (40)
Race:
Asian 16 (39) 4.86, 5 .43 .173
Black 7 (78) 30 (2.6-336) .006
MT 1 (50) 2.0 (.07-56) .693
PI 2 (50) 93 (.04-20) .964
U 21 (45) 1.3 (.44-3.5) .676
WH 81 (42) 1.4 (.60-3.3) .442
Product:
BM 18 (45) .33, 1 .857 .90 (.37-2.2) .826
PB 110 (44)
Ablate:
N 33 (44) .01, 1 .925 1.7 (.69-4.4) .240
Y 95 (43)
Graft:
Allo 102 (44) 1.98, 2 .371 .335
Auto 23 (40) 5.7 (.34-97) .227
Haplo 3 (75) 3.3 (.24-46) .371
Donor
HLA-IS 48 (44) 2.37, 4 .668 .229
HLA-MISR 3 (75) y
N/A 23 (40) y
URD-I 38 (42) .56 (.26-1.2) .123
URD-MIS 16 (49) 1.1 (.38-3.0) .902
AGVHD
N/A 25 (37) 3.57, 2 .168 .114
Yes 50 (41) 17 (1.1-260) .040
No 53 (51) 18 (1.2-285) .038
Both MV
None 21 (24) 58.3, 3 <.0005 <.0005
MV 24 (41) 2.3 (.99-5.3) .053
Vasopr 10 (20) .73 (.29-1.9) .505
Both MV
& V
76 (71) 8.0 (3.6-18) <.0005
ICU days
<5 53 (33) 15.1, 3 .002 .492
5-10 32 (47) .83 (.39-1.8) .630
10-15 20 (61) 1.8 (.69-4.7) .231
>15 22 (60) .91 (.36-2.3) .835
OR indicates odds ratio; CI, conﬁdence interval; MT, more than one race; PI,
Paciﬁc Islander; U, unknown; WH, white; BM, bone marrow; PB, peripheral
blood; Ablate, myeloablative conditioning regimen; N, no; Y, yes; Allo,
allogeneic; Auto, autologous; Haplo, haploidentical; IS, Identical Sibling;
MISR, mismatched relative; URD, unrelated donor; URD-I, unrelated
identical donor; URD-MIS ¼ mismatched unrelated donor; AGVHD, acute
GVHD; N/A, autologous donor; MV, mechanical ventilation; V, vasopressor.
* Variables entered in 4 blocks. Block (1): age, sex, race. Block (2): product,
ablate, graft, donor. Block (3): AGVHD, Mechanical ventilation, and/or
vasopressor. Block (4): ICU days.
y Nd ¼ Because of redundancy, degree of freedom reduced for donor.
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with patients transitioning to do-not-resuscitate or with-
drawal of life support [16].
Previous reports have found that vasopressor support,
mechanical ventilation, and dialysis were associated with
high mortality rates in BMT recipients [6-8]. Our results are
consistent with these ﬁndings. Vasopressor support and
mechanical ventilation were associated with signiﬁcant
mortality and those requiring both mechanical ventilation
and vasopressor support had the highest mortality (71%).
Improving communication between the medical teams
caring for acutely ill BMT patients and their families is a keycomponent of the ICU utilization project. In 1998, social
workers and nurses at Stanford conducted an end-of-life
survey. They interviewed 35 families who had lost a loved
one in the past year. Forty-seven percent of families felt they
received contradictory messages and 23% felt they received
conﬂicting recommendations for care. These ﬁndings indi-
cate a need for improved communication with the health
care team. The recommendations of the Robert Wood John-
son Foundation Critical Care End-of-Life Peer Workgroup
identiﬁed areas for improving the care of individuals at the
end of life, including patient and family-centered decision-
making, communication, and continuity of care [17]. Our goal
is clear, consistent, frequent, and empathetic communication
among all the health care teams, patients, and family mem-
bers. To address this goal, we have established and main-
tained a communication protocol.
One ongoing challenge is using the ICU criteria consis-
tently. There remain times when individuals are transferred
to the ICU although they fall into the category of no ICU
recommended. Between FY 2008 and FY 2014, 13 patients
accounted for14 ICU admissions in this category. All of these
cases were reviewed to determine why they were trans-
ferred. Two principle reasons were identiﬁed: (1) discussion
with patients and families did not occur well enough in
advance of the declining clinical situation to allow sufﬁcient
time to reshape goals of care, and (2) an acute event
precipitated transfer to the ICU before goals of care discus-
sions could occur. These scenarios emphasize the need to
discuss goals of care and complete an advanced care plan
(ACP) before transplantation. Ganti et al. explored the impact
of ACP on outcomes after BMT [18]. In this retrospective re-
view of 380 BMT recipients, 172 did not have an ACP and 127
had an ACP. Of the 127 patients with an ACP, 22% completed
the ACP before being diagnosed with a malignancy, 69%
completed the ACP in the time between the malignant
diagnosis and transplantation, and 9% completed the ACP
after transplantation. The only signiﬁcant predictive variable
for the completion of an ACP before transplantation was age
 40 years. Both the risk of death at 1 year after BMT and
overall risk of death were signiﬁcantly higher in individuals
without an ACP. Although we did not collect information
on ACP in this project, thoroughly preparing patients and
families for transplantation, including a discussion of the
patient’s wishes should events take a turn for the worse,
can decrease nonbeneﬁcial care, pain and suffering and
empower family or surrogate decisionmakers. For the health
care team working with critically ill BMT patients, prior
discussions of the patient’s goals, wishes, and values can
facilitate appropriate use of ICU resources and support the
patient and family when goals of care are shifted to comfort.
These a priori discussions can signiﬁcantly decrease the
stress for the families and the health care team.
Based on our historical data, patients transferred to the
ICU had a hospital mortality of 92%. Between FY 2008 to FY
2014, 128 of the 234 patients transferred to the ICU died, for
an overall hospital mortality of 55%. The reduction in hospital
mortality in this cohort compared with our historical data
may be because of our continual review and utilization of
our guidelines and avoidance of transferring individuals who
fall into the no ICU recommended category. The BMT team
makes signiﬁcant efforts to work with patients and families
who fall into the no ICU recommended category to reshape
goals of care and avoid transfer to the ICU. During this same
period (FY 2008 to FY 2014), 140 individuals who were
not transferred to the ICU died within the ﬁrst 100 days
P. Jenkins et al. / Biol Blood Marrow Transplant 21 (2015) 2023e2027 2027of transplantation. Causes of mortality included relapse
(n ¼ 50), acute GVHD (n ¼ 30), pulmonary toxicity/failure
(n ¼ 23), infection (n ¼ 19), liver toxicity (n ¼ 7), and other
causes (n¼ 11). Themajority of these individuals would have
likely been categorized into the no ICU recommended group.
Some decrease in mortality is also likely due to improve-
ments in the management of infections, sepsis, and respira-
tory failure.
We believe there are signiﬁcant beneﬁts to appropriate
ICU utilization. First and foremost is that the patients most
likely to beneﬁt from the specialized medical and nursing
care that can be provided in the ICU do receive the care. For
patients where no ICU is recommended, the goals of care
can shift to comfort and the patient and family can be
supported in a manner that respects the patient’s wishes
and provides comfort and dignity at the end of life. At the
institutional level, freeing ICU beds for patients most likely
to beneﬁt serves both the hospital and community. From
the perspective of rising health care costs, avoiding non-
beneﬁcial care can signiﬁcantly reduce health care costs. Our
ﬁnancial analysis indicates a signiﬁcant reduction in costs of
care if the patients in the no ICU recommended category had
been cared for on the BMT unit.
Limitations
These guidelines were developed and prospectively
monitored for utilization and impact on outcomes. One
limitation is that we categorized only those individuals
transferred to the ICU. Knowing the ICU category of those
who died and were not transferred to the ICU would be
another means of validating the reliability of the guidelines.
Another limitation is that the ﬁndings reﬂect the experience
of a single institution, whichmay limit generalizability. Other
BMT centers would need to review their own ICU utilization
data to determine if these same categories are appropriate
for their program. Incorporating additional information, such
as the HCT-CI, may improve the generalizability of the
guidelines and perhaps add further reﬁnement, particularly
in the challenging category of limited ICU recommended
where the outcomes at the time of ICU transfer are more
difﬁcult to predict [9,19].
Future Directions
In the future, reviewing both 6- and 12-month survival in
patients transferred to the ICU may reﬁne the ICU categories
and provide additional prognostic information to be used in
counseling patients and families. Incorporating other prog-
nostic criteria, such as the Sequential Organ Failure Score,
into our guidelines may enhance the ICU categories, partic-
ularly the challenging limited ICU recommended category
[7].
Another future goal is to increase the number of patients
who complete an ACP in the pretransplantation phase. All of
our BMT patients and families meet with a social worker
before transplantation to assess their level of understanding
of the illness and transplantation, discuss ﬁnancial concerns,
and assist with housing and disability forms. Importantly,
the social workers discuss ACP and assist patients and
families in completing advanced directives if they wish. Inhigh-risk patients, discussing the ICU categories in advance
of transplantation will help the BMT physician understand
the patient’s goals of care. In addition, we are considering
developing an addendum to the ACP to assist patients in
discussing their goals of care with the health care team.
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